It's tough to notch a double-digit gain on a stock in this market, but I'm thrilled to let you in on a little secret: Our subscribers to TheStreet.com Biotech Select have been guided to three double-digit calls within the last six months, courtesy of Adam Feuerstein, our in-house portfolio manager who runs the Biotech Select service.

On Sept. 24, Feuerstein added ImmunoGen ( IMGN) to the model portfolio of Biotech Select when its stock was selling at $4.90 a share. ImmunoGen is now at $7.01 a share, delivering a 43% total return to Biotech Select subscribers. Feuerstein knew that ImmunoGen is developing a second-generation version of the blockbuster breast cancer drug Herceptin in partnership with Roche. Early data on the drug has been very positive, which sparked Roche to accelerate its development.

Biotech Select

On Oct. 8, Feuerstein added Optimer Pharmaceuticals ( OPTR) to the Biotech Select model portfolio when it was trading at $6.50 a share. Optimer Pharmaceuticals closed recently at $12.90 a share, delivering a 98.5% total return so far to Biotech Select subscribers. Feuerstein added Optimer to the model portfolio because of the company's experimental drug OPT-80, a more effective and convenient antibiotic to target Clostridum difficile. (C. diff is a bacterial super bug that causes severe abdominal pain, bloating and diarrhea and can sometimes be fatal.) Soon after Feuerstein added Optimer to the model portfolio, its shares took off when the company reported positive phase III clinical trial results for OPT-80.

On Jan. 20, Feuerstein added CV Therapeutics ( CVTX) to the Biotech Select model portfolio when it was trading at $10.75 a share. Two months later, Feuerstein closed the position when Gilead Sciences ( GILD) announced a $20-per-share buyout of CV Therapeutics. The stock produced an 86% return for Biotech Select subscribers.
David Morrow is editor-in-chief of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He appreciates your feedback; click here to send him an email.

If you liked this article you might like

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

5 Stocks Poised for Breakouts